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Parkinson’s disease is a progressive neurodegenerative disorder, which affects the basal 
ganglia and the activity of dopamine, a neurotransmitter in the brain. This interruption of 
dopamine appears to provide a n explanation as to the loss of motor function by those who 
have Parkinson’s disease (PD). 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is 
a prodrug to MPP+, a known neurotoxin which induces Parkinsonian symptoms to those 
exposed to it. The goal of this study was to: 1) to investigate the potential for nicotine and 
velvet bean extract to protect against MPTP-induced neurotoxicity and 2) to establish a 
zebrafish (Danio rerio) model to study these effects of nicotine and L-DOPA from velvet 
beans.  Using high performance liquid chromatography, the concentration of velvet bean 
L-DOPA, a precursor to dopamine, was determined.  In cell culture studies, the effects of 
nicotine or velvet bean extract on reducing neuroinflammation was then investigated. In 
behavioral experiments, the effects of nicotine and MPTP are being investigated. Reports 
from the American Academy of Neurology suggest that people who smoke cigarettes are 
~44% less likely to develop Parkinson’s disease, compared to those who have never 
smoked this research can help elucidate nicotine’s putative role in mitigating 
inflammation associated with PD. 
 
